To characterize molecular mechanism involved in pancreatic carcinogenesis, we analysed gene-expression profiles of 18 pancreatic tumors using a cDNA microarray representing 23 040 genes. As pancreatic ductal adenocarcinomas usually contain a low proportion of cancer cells in the tumor mass, we prepared 95% pure populations of pancreatic cancer cells by means of laser microbeam microdissection, and compared their expression profiles to those of similarly purified, normal pancreatic ductal cells. We identified 260 genes that were commonly upregulated and 346 genes that were downregulated in pancreatic cancer cells. Because of the high degree of purity in the cell populations, a large proportion of genes that we detected as upregulated or downregulated in pancreatic cancers were different from those reported in previous studies. Comparison of clinicopathological parameters with the expression profiles indicated that altered expression of 76 genes was associated with lymph-node metastasis and that of 168 genes with liver metastasis. In addition, expression levels of 30 genes were related to the recurrence of disease. These genome-wide expression profiles should provide useful information for finding candidate genes whose products might serve as specific tumor markers and/or as molecular targets for treatment of patients with pancreatic cancer.
Introduction
The mortality among patients with pancreatic cancer is worse than for any other kind of malignant tumor, with a 5-year survival rate only 4% (Greenlee et al., 2001) . The poor prognosis of this malignancy reflects both the difficulty of early diagnosis and a generally poor response to current therapies (DiMagno et al., 1999; Greenlee et al., 2001) . In particular, no specific tumor marker is clinically available for detection of this disease at an early and potentially curative stage, although CA19-9 has been used as tumor marker for pancreatic cancers. Surgical resection is the only possible cure at present, but cases that are surgically resectable at diagnosis account for fewer than 20% of patients with this cancer (DiMagno et al., 1999; Klinkenbijl et al., 1999) . Endoscopic ultrasonography (EUS), endoscopic retrograde cholangiopancreography (ERCP), and spiral CT are available to screen individuals at risk for familial pancreatic cancer (Brentnall et al., 1999) , but those approaches are not practical in terms of time and cost effectiveness to screen every asymptomatic individual. Hence, tumor markers that are sensitive and specific for pancreatic cancer must be discovered before we can see improvement in the prognosis of this devastating disease.
Almost all patients at an advanced stage fail to respond to any treatment. To overcome that situation, some clinical trials have been attempting to establish therapeutic strategies on the basis of molecular technologies. Such trials have involved, for example, an MMP inhibitor, drugs designed to inhibit Ras farnesyltransferase, and antibody-based approaches (Rosenberg, 2000; Laheru et al., 2001; Hao and Rowinsky, 2002) . However, so far, these experiments have achieved no remarkable effects on this disease.
Some studies describing gene expression profiles of pancreatic cancers have discovered genes that might be candidates as diagnostic markers or therapeutic agents (Crnogorac-Jurcevic et al., 2002; Han et al., 2002; Iacobuzio-Donahue et al., 2002) . However, data derived from tumor masses cannot adequately reflect expressional changes during pancreatic carcinogenesis, because a typical pancreatic ductal adenocarcinoma exists as a solid mass with a highly desmoplastic stromal reaction containing various cellular components. The proportions of neoplastic cells in such tissue samples are quite different from one case to another, ranging from 5 to 55%. Therefore, previously published results are likely to reflect heterogeneous expression profiles. Furthermore, since pancreatic adenocarcinomas are generated from normal pancreatic ductal epithelium, a cell type that accounts for less than 5% of pancreatic tissue, analyses that use normal human pancreas for control cells are inappropriate for investigating genes related to carcinogenesis and/or progression of cancer in that organ.
With these issues in view, we prepared purified populations of cancer cells and normal ductal cells by means of laser microbeam microdissection (LMM), and analysed genome-wide gene expression profiles of 18 pancreatic tumors using a cDNA microarray representing 23 040 genes. Through the expression profiles, we identified the genes whose expression was significantly associated with some clinical parameters, such as lymph node metastasis, liver metastasis, and recurrence risk. These data should provide not only important information about pancreatic carcinogenesis, but should identify candidate genes whose products might serve as diagnostic markers and/or as molecular targets for treatment of patients with pancreatic cancer.
Results

Isolation of pancreatic cancer cells and normal pancreatic ductal epithelial cells using LMM
To obtain precise expression profiles of pancreatic cancer cells, we employed LMM to avoid contamination of the samples by noncancerous cells. Since pancreatic cancer originates from pancreatic ductal cells, we used similarly purified populations of normal pancreatic ductal epithelial cells as controls. As the great majority of cells in the pancreas are acinar cells, we considered it inappropriate to use the entire pancreas to screen for genes associated with carcinogenesis in that organ. Figure 1 shows micrographs of representative cancers (a and b), and normal pancreatic duct (c and d) after microdissection. In these histological views of a welldifferentiated type (a) and a scirrhous type (b) of invasive ductal adenocarcinoma, the proportions of cancer cells were estimated to be about 30 and 10%, respectively. We estimated that the proportion of cancer cells in the LMM-purified samples used for our expression analysis was at least 95%.
We also examined the proportion of acinar cells that were contaminating the microdissected population of normal pancreatic ductal epithelial cells serving as a universal control, by measuring the signal intensity of a 
Filtering of data
A gene expression analysis of 18 pancreatic cancers on a cDNA microarray representing approximately 23 000 genes identified 260 genes that were commonly upregulated more than fivefold over their levels in normal pancreatic ductal epithelial cells (Supplemental Table 1 ; also see Materials and methods). In particular, 167 of them were expressed at a level more than 10-fold higher than in normal ductal cells. Among the 260 upregulated genes, the biological functions of 197 were already known to some extent. Of them, interferoninduced transmembrane protein 1 (IFITM1), plasminogen activator, urokinase (PLAU), prostate stem cell antigen (PSCA), S100 calcium binding protein P (S100P), RNA binding motif single-stranded interacting protein 1 (RBMS1), and baculoviral IAP repeatcontaining 5 (BIRC5) had already been reported as overexpressed in pancreatic cancers (Han et al., 2002; Iacobuzio-Donahue et al., 2002) . The list of upregulated elements included genes encoding transcriptional factors and proteins involved in the signal transduction pathway, in the cell cycle, and in cell adhesion (Table 1) .
On the other hand, we identified 346 genes whose expression ratio was reduced to less than 0.2 in pancreatic cancer cells (Supplemental Table 2 ). Among them, 212 had been functionally characterized to some extent. They included AXIN1 upregulated 1 (AXUD1), deleted in liver cancer 1 (DLC1), growth arrest and DNA-damage-inducible, beta (GADD45B), and P53-dependent damage-inducible nuclear protein 1 (p53DINP1), all of which have been implicated in growth suppression (Yuan et al., 1998; Satoh et al., 2000; Ishiguro et al., 2001; Okamura et al., 2001) .
Verification of selected genes by semiquantitative RT-PCR
To validate the expression data obtained by microarray analysis, we performed semi-quantitative RT-PCR experiments for 12 genes that were strongly overexpressed in almost all informative cases: ATP1B3, ARHGDIB, APP, BIRC5, CDH3, EphA4, GYS1, KPNB2, RBMS1, REGIV, S100P, and VANGL1. The results of the RT-PCR analysis were highly concordant with microarray data in the great majority of the tested cases (Figure 2 ).
Identification of genes correlated with clinicopathological features
Lymph node metastasis and liver metastasis In order to investigate relations between gene expression profiles and clinicopathological parameters, we searched genes that were possibly associated with lymph-node metastasis and liver metastasis, which are important determining factors of patients' prognosis. We first examined the expression profiles and the status of lymph-node metastasis using nine lymph-node-positive and four node-negative cases, and identified 76 genes that were associated with lymph-node status by a random permutation (P-value o0.05) ( Table 2 ). Of these, 35 genes were relatively upregulated, and 41 genes were downregulated in node-positive tumors (Figure 3 ). In addition, we compared expression profiles of five cases with predominant recurrence in liver with those of six cases with metastasis to other sites (local, peritoneal, and chest). We identified 168 genes that showed altered expression patterns uniquely in cases that had liver metastasis (Table 3) , and 60 of them were relatively upregulated in tumors (Figure 4 ). These genes included some key factors that had been proposed to play crucial roles in tumor cell proliferation, invasion, and metastasis: integrin, beta 4 (ITGB4) (Shaw et al., 1997) , colony stimulating factor 1 (CSF1) (Chambers et al., 1997) , basigin (BSG) (Guo et al., 2000) , and kinesin-like 6 (KNSL6) (Scanlan et al., 2002) . Hierarchical clustering analysis using these identified gene sets was also able to clearly classify the groups with regard to lymph-node status or those with liver metastasis (Figures 3 and 4 ).
Prognosis
To further investigate genes that might be associated with prognosis, we compared expression profiles of seven cases who had recurrence within 12 months after surgery (disease-free interval o12 months; median 6.4 months) with those of six cases who had 412 months of disease-free interval (median 17.0 months). As shown in Figure 5a , we identified 84 genes that were expressed differently between these two groups using a random permutation method (Po0.05).
In attempt on establishment of a predictive scoring system using gene expression pattern for recurrence after surgery, we rank ordered the above prognostic 84 candidate genes on the basis of the magnitude of their permutation P-values (Table 4) and calculated the prediction score by the leave-one-out test for crossvalidation using top 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80 , and 84 genes on the rank-ordered list. To determine the number of discriminating genes giving the best separation of the two groups, we calculated a classification score (CS) for each gene set ( Figure 5b ). As shown in Figure 5c , the best separation was obtained when we used the top 30 genes in our candidate list for scores calculation.
Discussion
The cDNA microarray is a powerful tool for identifying genes that may be applicable for development of novel diagnostic markers and molecular targets for therapeutic purposes (Ishiguro et al., 2002; Yagyu et al., 2002) . A few groups already have reported gene expression profiles of pancreatic cancer (Crnogorac-Jurcevic et al., 2002; Han et al., 2002; Iacobuzio-Donahue et al., 2002; Logsdon et al., 2003) , but the results reported here are quite different from the others, probably for the reasons described below.
First, a microarray analysis using clinical samples is not easy because various cellular components contaminate normal as well as cancer tissues. Pancreatic ductal adenocarcinomas are good examples in this respect because their highly desmoplastic stromal reactions result in a low proportion of cancer cells in the tumor mass. Furthermore, in the normal pancreas, acinar cells and islets account for more than 95% of this organ, and epithelial cells in the pancreatic duct, from which the carcinoma originates, correspond to a very small percentage of the total (Bockman et al., 1983; Hruban et al., 2000) . Therefore, an analysis of gene expression profiles using bulk tissues from cancerous and normal whole pancreas is significantly influenced by the particular mixture of cells in the tissues examined; proportional differences of acinar cells, islet cells, Analysis of expression profiles in pancreatic cancers T Nakamura et al fibroblasts, and inflammatory cells can mask significant increases or decreases in the expression of genes involved in pancreatic carcinogenesis. Hence, in this study, we used an LMM system to purify as much as possible the populations of cancerous and normal epithelial cells obtained from surgical specimens (Gjerdrum et al., 2001; Kitahara et al., 2001) . Because it is possible to microdissect even a single cell with LMM, this technology is crucial for achieving an effective microarray analysis of pancreatic cancer specimens ( Figure 1 ). To evaluate the purity of microdissected cell populations, we analysed expression of the AMY1A gene, which is expressed specifically in acinar cells. After the dissection procedure, the proportion of contaminating acinar cells among the normal pancreatic ductal epithelial cells was estimated to be smaller than 0.29% (see Materials and methods). In addition to AMY1A, we examined expression levels of other genes that are highly expressed in acinar cells, for example, elastase 1, trypsin 1, and pancreatic lipase, and obtained similar results (data not shown); the purity of cell populations subjected to the LMM technique could therefore be as high as 99.7%. Second, the quality of RNA extracted from clinical tissue, particularly from pancreas, is extremely important. The pancreas is rich in RNase, and degradation of Analysis of expression profiles in pancreatic cancers T Nakamura et al RNA occurs very rapidly. We examined the quality of the RNA extracted from each specimen by visualizing the 28S and 18S ribosomal RNAs after electrophoresis on denaturing agarose gels, and selected samples for which we clearly observed bands corresponding to both ribosomal RNAs. Eventually, we selected 18 pancreatic cancers (32%) among 56 surgical resections, because pancreatic RNA from the other 38 patients was of poor quality (data not shown).
Careful purification of cancer cells and normal epithelial ductal cells, subsequent RNA isolation, and cDNA microarray analysis identified 260 genes whose expression was commonly upregulated according to the criteria described in Materials and methods section. As expected, in view of differences between the materials used in this study as opposed to previous reports, such as the quality of cancer cells and the number of genes on the microarray, most of our data differed from those reported previously (Crnogorac-Jurcevic et al., 2002; Iacobuzio-Donahue et al., 2002) . However, we are confident that our own study is the first to provide precise and genome-wide gene expression profiles of pancreatic cancers on a large scale.
We identified 260 genes that were overexpressed to at least a fivefold greater extent in cancer cells than in normal pancreatic epithelial cells (Supplemental Table 1 ). Such genes could have immediate diagnostic potential, and those known to be critical for tumor growth also would have therapeutic potential. Some, such as regenerating gene type IV (REGIV), ephrin and vang (van gogh, Drosophila)-like 1 (VANGL1), might well serve as molecular targets for new therapeutic agents.
REGIV was overexpressed in all of the informative pancreatic cancer cases we examined, and its overexpression was confirmed in seven of the 12 pancreatic cancers examined by semi-quantitative RT-PCR. Since the REGIV gene product is suspected to be a secretory protein on the basis of its amino-acid sequences, and in fact its secretion has been detected in the culture medium of HT29-5M12 cells (Violette et al., 2003) , it might represent a candidate tumor marker. Analysis of expression profiles in pancreatic cancers T Nakamura et al Figure 3 Dendrogram of two-dimensional hierarchical clustering analysis using 76 genes selected by a random permutation test that compared expression profiles of nine lymph-node-positive cases with those of four lymph-node-negative cases. In the vertical axis, 35 genes were clustered in the upper branch, indicating relatively high levels of expression in lymph-node-positive cases Analysis of expression profiles in pancreatic cancers T Nakamura et al Analysis of expression profiles in pancreatic cancers T Nakamura et al Analysis of expression profiles in pancreatic cancers T Nakamura et al VANGL1 was overexpressed in all of the informative pancreatic cancers according to our microarray data, and its high expression was also confirmed by semiquantitative RT-PCR. The VANGL1 product, which contains four putative transmembrane domains, was expressed specifically in testis and ovary among 29 normal tissues examined elsewhere (Yagyu et al., 2002) . This gene is also highly and frequently transactivated in hepatocellular carcinomas. Since enforced reduction of its expression has induced apoptosis in hepatocellular carcinomas (Yagyu et al., 2002) , the gene product is likely to be another good candidate for development of novel anticancer drugs. Among the numerous other genes that were highly overexpressed in the pancreatic cancers we examined, those whose products are putative membranous or secreted proteins are all potential targets for novel anticancer drugs or for serological diagnostic markers to aid early detection.
We also identified 346 genes that were significantly downregulated in pancreatic cancer cells (Supplemental Table 2 ), but the functions of 135 of them are unknown at present. Since the pancreatic duct epithelial cell is the progenitor of pancreatic ductal cancer, our data were obtained by comparing purified populations of cancer cells with origin cells. Therefore, the set of genes listed here reflects specific downregulation during Figure 4 Dendrogram of two-dimensional hierarchical clustering analysis using 168 genes selected by a random permutation test that compared expression profiles of five liver-metastasis-positive cases with those of six negative cases. In the vertical axis, 60 genes were clustered in the upper branch, which was more highly expressed in liver-metastasis-positive cases Analysis of expression profiles in pancreatic cancers T Nakamura et al transformation from normal epithelial cells to cancer cells. Although downregulation of genes can be either the cause or the result, some of the genes listed here are likely to encode tumor suppressors. Some known suppressor genes for pancreatic cancer, such as SMAD4, TP53, INK4A, and BRCA2 (Rozenblum et al., 1997; Goggins et al., 2000) , do not appear on our list of downregulated genes, but others known to be involved in tumor suppression or apoptosis, such as AXIN1 upregulated 1 (AXUD1), deleted in liver cancer 1 (DLC1), growth arrest and DNA-damage-inducible, beta (GADD45B), p53-dependent damage-inducible nuclear protein 1 (p53DINP1), are included. AXUD1, a nuclear protein, is induced in response to elevation of axin; the latter is a key mediator of the Wnt signaling pathway and is important for axis formation during early development. As dysfunction or downregulation of the Wnt signaling pathway is observed often in human tumors (Satoh et al., 2000; Ishiguro et al., 2001) , this gene product may have a tumor suppressor function; our data imply that downregulation of AXUD1 might lead to downregulation of this signaling pathway and then to pancreatic carcinogenesis. Deleted in liver cancer 1 (DLC1) is a candidate tumor suppressor gene for human liver cancer as well as for prostate, lung, colorectal, and breast cancers. DLC1 is highly similar in sequence to rat p122 RhoGap, which negatively regulates Rho GTPases. Hence, downregulation of DLC1 is considered to result in constitutive activation of the Rho-Rho-kinase pathway and to lead to oncogenic malignant transformation (Yuan et al., 1998; Ng et al., 2000) . These observations suggest that pancreatic carcinogenesis involves complicated and diverse pathways. Figure 5 (a) Result of a two-dimensional hierarchical clustering analysis using 84 genes selected by a random permutation test that compared expression profiles of seven early-recurrent cases (within 12 months after surgery) with those of six late-recurrent cases (over 12 months after surgery). In the vertical axis, 84 genes were clustered in different branches according to similarity in relative expression ratios. (b) Optimization of the number of discriminating genes. The classification score (CS) was calculated by using the prediction score of early-recurrent case (PS r ) and late-recurrent case (PS n ) in each gene set, as follows:
A larger value of CS indicates better separation of the two groups by the predictive scoring system. (c) Different prediction scores appear when the number of discriminating genes is changed. Red diamonds represent early-recurrent cases; blue diamonds denote laterecurrent cases Analysis of expression profiles in pancreatic cancers T Nakamura et al Analysis of expression profiles in pancreatic cancers T Nakamura et al Pancreatic cancer is characterized by very aggressive progression and rapid recurrence after surgical treatment. It has been reported that the cumulative 1-, 3-, and 5-year disease-free survival rates were 66, 7, and 3% respectively, and median disease-free survival time was only 8 months (Sperti et al., 1997) . Most common recurrent sites are the local region and the liver, and distant metastases appear in the peritoneal cavity. However, since the relationships between tumor characteristics and the recurrence patterns are still little understood, we compared the expression profiles to lymph node status or liver metastasis. We identified 76 genes that might be associated with lymph-node status, and 168 genes with liver metastasis. These genes included some key molecules whose possible roles in tumor progression had been reported previously: ITGB4 and BSG were upregulated in lymph-node-positive cases, and KNSL6 and KRT8 were relatively upregulated in liver metastasis cases. ITGB4 was reported to promote carcinoma invasion through a preferential and localized targeting of phosphoinositide-3 OH kinase activity (Shaw et al., 1997) , supporting the possible involvement of ITGB4 in lymph node metastasis. KNSL6, a member of the kinesin family of motor proteins, is known to be involved in chromosome segregation during mitosis (Maney et al., 1998) . The transcript of KNSL6 was highly expressed in colon cancer, and was identified as cancer antigens associated with a cancer-related serum IgG response (Scanlan et al., 2002) . Thus, this antigen could be a biological marker for diagnosis and for the monitoring of recurrence site.
In addition, we identified 84 genes possibly associated with tumor recurrence of pancreatic cancers. Expression levels of a subset of 30 genes selected from these 84 genes would be useful for predicting the disease-free interval after surgical operation ( Figure 5 ). These results might be useful for selection of patients for active adjuvant therapy although larger-scale study will be required to further evaluate our prediction system.
Cancer therapies directed at specific molecular alterations that occur in cancer cells have been validated through clinical development and regulatory approval of anticancer drugs such as trastuzumab (Herceptin) for the treatment of advanced breast cancer, imatinib methylate (Gleevec) for chronic myeloid leukemia, gefitinib (Iressa) for non-small cell lung cancer (NSCLC), and rituximab (anti-CD20mAb) for B-cell lymphoma and mantle cell lymphoma (Fang et al., 2000; Ciardiello and Tortora, 2001; Slamon et al., 2001; Rehwald et al., 2003) . These drugs are clinically effective and better tolerated than traditional anticancer agents because they target only transformed cells. Hence, such drugs not only improve survival and quality of life for cancer patients, but also validate the concept of molecularly targeted cancer therapy. Furthermore, targeted drugs can enhance the efficacy of standard chemotherapy when used in combination with it (Gianni, 2002; Klejman et al., 2002) . Therefore, future cancer treatments will probably involve combining conventional drugs with target-specific agents aimed at different characteristics of tumor cells such as angiogenesis and invasiveness.
Despite the success of the anticancer drugs mentioned above, no specific molecular-targeted drugs or tumor markers except CA19-9 have yet been developed for diagnosis or treatment of patients with pancreatic cancer. The poor prognosis of this disease is due to both the difficulty of diagnosis at an early stage and a generally poor response to current therapeutic methods; at present, no effective treatment is available for patients at an advanced stage. Hence, sensitive and specific tumor markers for pancreatic cancer, as well as new therapeutic approaches, are urgently required. The extensive list reported here of genes that are up-or downregulated in pancreatic cancers should provide useful information for a better understanding of the precise mechanisms of tumorigenesis in this vital organ, and for identifying molecules to serve as molecular targets for early diagnosis and treatment of pancreatic cancer.
Materials and methods
cDNA microarray
We fabricated a genome-wide cDNA microarray with 23 040 cDNAs selected from the UniGene database (build #131) of Analysis of expression profiles in pancreatic cancers T Nakamura et al the National Center for Biotechnology Information (NCBI). This microarray system was constructed essentially as described previously (Ono et al., 2000) . Briefly, the cDNAs were amplified by RT-PCR using poly (A) þ RNAs isolated from various human organs as templates; the lengths of the amplicons ranged from 200 to 1100 bp, without any repetitive or poly (A) sequences.
Tissue samples and microdissection
Tissue samples from pancreatic cancers (n ¼ 18) and from normal pancreas (n ¼ 7) were obtained from surgical specimens, concerning which all patients had given informed consent. All cancer tissues had been confirmed histologically as invasive ductal carcinomas by the pathologist; clinical information was obtained from medical records (four female and 14 male patients; median age 65.0 with range 46-77 years). Clinical stage was judged according to the UICC TNM classification. Since almost all pancreatic ductal cells from corresponding blocks of normal tissue showed dysplastic changes, mostly because of downstream obstruction of the duct, ductal cells from only four of the 18 patients were suitable for use as normal controls. Hence, we obtained normal pancreatic ductal cells from three patients who had undergone pancreatoduodenectomy for cholangiocarcinoma, duodenal leiomyosarcoma, or ampullary tumor. These normal pancreatic duct cells were observed as a normal epithelium pathologically, and they were not dysplasia. All specimens were harvested immediately after surgical resection and were embedded in TissueTek OCT medium (Sakura, Tokyo, Japan) before storage at À801C. The frozen tissues were cut into 8 mm sections using a cryostat (Sakura, Tokyo, Japan) and then stained with hematoxylin and eosin for histological examination. Pancreatic carcinoma cells and normal pancreatic ductal epithelial cells were isolated selectively using the EZ cut system with a pulsed ultraviolet narrow beam-focus laser (SL Microtest GmbH, Germany) in accordance with the manufacturer's protocols. After microdissection, the seven populations of normal ductal epithelial cells were mixed to make a 'universal control' for all 18 cancer samples.
RNA extraction, T7-based RNA amplification, and hybridization Total RNAs were extracted from each sample of lasermicrodissected cells into 350 ml of RLT lysis buffer (QIAGEN, Hilden, Germany). The extracted RNAs were treated for 30 min at room temperature with 30 U of DNase I (Roche, Basel, Switzerland) in the presence of 1 U of RNase inhibitor (TOYOBO, Osaka, Japan) to remove any contaminating genomic DNA. After inactivation at 701C for 10 min, the RNAs were purified with an RNeasy Mini Kit (QIAGEN) according to the manufacturer's recommendations. All of the DNase I-treated RNAs were subjected to T7-based RNA amplification; two rounds of amplification yielded 50-100 mg of aRNA from each sample. Then 2.5 mg aliquots of aRNA from cancer cells or normal pancreatic ductal epithelial cells were labeled by reverse transcription with Cy5-dCTP or Cy3-dCTP (Amersham Biosciences), respectively, as described previously (Ono et al., 2000) . Hybridization, washing, and scanning were also carried out according to methods described previously (Ono et al., 2000) .
Data analysis
Signal intensities of Cy3 and Cy5 from the 23 040 spots were quantified and analysed by substituting backgrounds, using ArrayVision software (Imaging Research, Inc., St Catharines, Ontario, Canada). Subsequently, the fluorescent intensities of Cy5 (tumor) and Cy3 (control) for each target spot were adjusted so that the mean Cy3/Cy5 ratio of 52 housekeeping genes on the array was equal to one. Because data derived from low signal intensities are less reliable, we determined a cutoff value on each slide as described previously (Ono et al., 2000) and excluded genes from further analysis when both Cy3 and Cy5 dyes yielded signal intensities lower than the cutoff (Saito-Hisaminato et al., 2002) . For other genes, we calculated the Cy5/Cy3 ratio using the raw data of each sample.
We identified up-or downregulated genes common to pancreatic cancer according to the following criteria: (1) genes for which we were able to obtain expression data in more than 50% (at least nine of the 18 cases) of the cancers examined; and (2) genes whose expression ratio was more than 5.0 in pancreatic cancer cells (defined as upregulated genes) or genes whose expression ratio was less than 0.2 (defined as downregulated genes) in more than 50% of informative cases. Additionally, we further selected genes according to the following criteria: (1) genes for which we were able to obtain expression data in six, seven, or eight cases; and (2) genes whose expression ratio was more than 5.0 in all of the informative cases.
Calculation of contamination percentage
Pancreatic amylase (AMY1A), an enzyme expressed exclusively in pancreatic acinar cells, was used to evaluate the proportion of acinar cells present in the population of microdissected normal pancreatic ductal epithelial cells. Each intensity was normalized to the intensity of the beta actin gene (ACTB) as follows:
(Ratio A) the AMY1A/ACTB intensity ratio in whole pancreas (where most of the cells correspond to acinar cells); the signal intensity of poly (A) þ RNA isolated from normal whole pancreas pooled from nine individuals (Clontech) was 96.74.
(Ratio B) the AMY1A/ACTB intensity ratio in microdissected normal ductal epithelial cells ¼ 0.28 (the average of signal intensities from 18 hybridizations using a mixture of normal pancreatic ductal cells from seven individuals as a universal control).
The contamination percentage was calculated as (Ratio B)/ (Ratio A) Â 100 ¼ 0.29%.
Identification of genes responsible for clinicopathological data
Genes associated with clinicopathological features, such as lymph node positive (r) and negative (n), liver metastasis positive (r) and negative (n), and early recurrence (r) and late recurrence (n), were chosen according to following two criteria: (i) signal intensities are higher than the cutoff value in at least 80% of the cases; and (ii) |Med r ÀMed n |X0.5, where Med indicates the median derived from log-transformed relative expression ratios in two groups. Genes were selected as candidates when they met the criteria with a permutation P-value of smaller than 0.05 in each clinicopathological status.
First, we applied a random permutation test to identify genes that were expressed differently in the two groups. The mean (m) and standard deviation (s) were calculated from the log-transformed relative expression ratios of each gene in node-positive (r) and node-negative (n) cases, liver-metastasispositive (r) and -negative (n), and early recurrence (r) and late recurrence (n), respectively. A discrimination score (DS) for each gene was defined as follows:
DS ¼ ðm r À m n Þ=ðs r þ s n Þ Analysis of expression profiles in pancreatic cancers T Nakamura et al
We carried out permutation tests to estimate the ability of individual genes to distinguish between two groups; samples were randomly permutated between the two classes 10 000 times. Since the DS data set of each gene showed a normal distribution, we calculated a P-value for the user-defined grouping (Golub et al., 1999) . For this analysis, we applied the expression data of 13 cases consisting of four lymphnode-positive and nine-negative cases, those of 11 cases consisting of five liver-metastasis-positive and six -negative cases, and those of 13 cases consisting of seven early-recurrent cases and six late-recurrent cases. For these, analyses were performed by using only Stage IV cases according to UICC TNM classification.
Calculation of prediction score
We further calculated the prediction score of recurrence according to procedures described previously (Golub et al., 1999) . Each gene (g i ) votes for either early-recurrent cases or late-recurrent cases depending on whether the expression level (x i ) in the sample is closer to the mean expression level of earlyrecurrent cases or late-recurrent cases in reference samples. The magnitude of the vote (v i ) reflects the deviation of the expression level in the sample from the average of the two classes:
We summed the votes to obtain total votes for the earlyrecurrent cases (V r ) and late-recurrent cases (V n ), and calculated PS values as:
reflecting the margin of victory in the direction of either earlyrecurrent cases or late-recurrent cases. PS values range from À100 to 100; a higher absolute value of PS reflects a stronger prediction.
Evaluation of classification and leave-one-out test
We calculated the classification score (CS) by using the prediction score of early-recurrent (PS r ) and late-recurrent cases (PS n ) in each gene set, as follows:
A larger value of CS indicates better separation of the two groups by the predictive scoring system. For the leave-one-out test, one sample is withheld, the permutation P-value and mean expression levels are calculated using remaining samples, and the class of the withheld sample is subsequently evaluated by calculating its prediction score. We repeated this procedure for each of the 13 samples.
Semi-quantitative RT-PCR
We selected 12 highly upregulated genes and examined their expression levels by means of semi-quantitative RT-PCR experiments. A 3 mg aliquot of aRNA from each sample was reverse transcribed to single-stranded cDNAs using random primer (Roche) and Superscript II (Invitrogen). Each cDNA mixture was diluted for subsequent PCR amplification with the same primer sets that were prepared for the target DNA-or alpha tubulin-specific reactions (Table 5) . Expression of alpha tubulin served as an internal control. PCR reactions were optimized for the number of cycles to ensure product intensity within the linear phase of amplification.
